Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

View suggested citation Summary What is already known about this topic? Previously, inactivated polio vaccine (IPV) recommendations for U.S. adults addressed adults known to be at increased risk for poliovirus exposure. What is added by this report? On June 21, 2023, the Advisory Committee on Immunization Practices issued an IPV recommendation for all adults known or suspected to be unvaccinated or incompletely vaccinated against polio. Risk-based recommendations for IPV boosters have not changed. What are the implications for public health practice? Adults aged ≥18 years who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary polio vaccination series with IPV. Fully vaccinated adults at increased risk for poliovirus exposure may receive a single lifetime booster dose of IPV. Article Metrics Altmetric: X (22) Facebook (1) Citations: Views: Views equals page views plus PDF downloads Metric Details Related Materials Article PDF Full Issue PDF Abstract Poliovirus can cause poliomyelitis and lifelong paralysis. Although wild poliovirus types 2 and 3 have been eradicated, wild poliovirus type 1 and vaccine-derived polioviruses are still circulating in multiple countries worldwide. In 2022, a case of paralytic polio caused by vaccine-derived poliovirus type 2 was identified in an unvaccinated young adult in New York. This case and subsequent detection of community transmission underscored the ongoing risk for importation of poliovirus into the United States and risk for poliomyelitis among unvaccinated persons. However, previous Advisory Committee on Immunization Practices (ACIP) recommendations for adult polio vaccination were limited to adults known to be at increased risk for exposure. During October 2022–June 2023, the ACIP Polio Vaccine Work Group reviewed data on poliovirus surveillance and epidemiology, safety and effectiveness of inactivated poliovirus vaccine (IPV), and other considerations outlined in the ACIP Evidence to Recommendations Framework. On June 21, 2023, ACIP voted […]

Click here to visit source. Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2023